MRCP UK EXAMINATIONS

Detailed explanation-1: -COVID‐19 ARDS causes the typical ARDS pathological changes of diffuse alveolar damage in the lung. 6, 7 As patients move through the course of their illness, the longer term outcomes of ARDS are being reported, with lung fibrosis appearing as part of COVID‐19 ARDS.

Detailed explanation-2: -Serious complications in COVID-19 ARDS cases: pneumothorax, pneumomediastinum, subcutaneous emphysema and haemothorax-PMC. The . gov means it’s official.

Detailed explanation-3: -When this occurs, COVID-19 can lead to ARDS, typically setting in about eight days after the onset of initial symptoms. Certain risk factors increase the likelihood of the development of ARDS in people with COVID-19, including advanced age, diabetes, and high blood pressure.

Detailed explanation-4: -Conclusions: COVID-19 ARDS bears several similarities to viral ARDS but demonstrates lower minute ventilation and lower systemic levels of IL-6 compared with bacterial and culture-negative ARDS. COVID-19 ARDS was associated with longer dependence on mechanical ventilation compared with non-COVID-19 ARDS.

Detailed explanation-5: -The mortality from COVID-19 appears driven by the presence of severe ARDS, and ranges widely, from 12 to 78 percent with an average of 25 to 50 percent. However, death can occur from several other conditions including cardiac arrythmia, cardiac arrest, and pulmonary embolism.